Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

1 Day OWL 0.84% DJIA 0.02% S&P 500 0.24% Financial Services -0.02% ...